Literature DB >> 22451621

Clinical measurement of von Willebrand factor by fluorescence correlation spectroscopy.

Richard Torres1, Jonathan R Genzen, Michael J Levene.   

Abstract

BACKGROUND: Identification of von Willebrand factor (vWF) abnormalities in a variety of conditions is hampered by the limitations of currently available diagnostic tests. Although direct multimer visualization by immunoelectrophoresis is a commonly used method, it is impractical as a routine clinical test. In this study, we used a biophysical analysis tool, fluorescence correlation spectroscopy (FCS), to measure vWF distributions. The goals were to develop a method that is quicker and simpler than vWF gel electrophoresis and to evaluate the potential of FCS as a clinical diagnostic technique.
METHODS: We analyzed plasma from 12 patients with type 1 von Willebrand disease (vWD), 14 patients with type 2 vWD, and 10 healthy controls using a fluctuation-based immunoassay approach.
RESULTS: FCS enabled identification and proper classification of type 1 and type 2 vWD, producing quantitative results that correspond to qualitative gel multimer patterns. FCS required minimal sample preparation and only a 5-min analysis time.
CONCLUSIONS: This study represents the first implementation of FCS for clinical diagnostics directly on human plasma. The technique shows potential for further vWF studies and as a generally applicable laboratory test method.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22451621      PMCID: PMC3733381          DOI: 10.1373/clinchem.2011.179200

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  12 in total

1.  Detection of red cell aggregation by low shear rate viscometry in whole blood with elevated plasma viscosity.

Authors:  J Janzen; T G Elliott; C J Carter; D E Brooks
Journal:  Biorheology       Date:  2000       Impact factor: 1.875

2.  Understanding the role of von Willebrand factor and its cleaving protease ADAM TS13 in the pathophysiology of critical illness.

Authors:  Trung C Nguyen; Joseph A Carcillo
Journal:  Pediatr Crit Care Med       Date:  2007-03       Impact factor: 3.624

Review 3.  Laboratory testing for von Willebrand disease: toward a mechanism-based classification.

Authors:  Richard Torres; Yuri Fedoriw
Journal:  Clin Lab Med       Date:  2009-06       Impact factor: 1.935

4.  Von Willebrand factor assay proficiency testing. The North American Specialized Coagulation Laboratory Association experience.

Authors:  Wayne L Chandler; Ellinor I B Peerschke; Donna D Castellone; Piet Meijer
Journal:  Am J Clin Pathol       Date:  2011-06       Impact factor: 2.493

5.  Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure.

Authors:  Tomoko Ono; Jun Mimuro; Seiji Madoiwa; Kenji Soejima; Yuji Kashiwakura; Akira Ishiwata; Katsuhiro Takano; Tsukasa Ohmori; Yoichi Sakata
Journal:  Blood       Date:  2005-09-27       Impact factor: 22.113

6.  Fluorescence correlation spectroscopy. II. An experimental realization.

Authors:  D Magde; E L Elson; W W Webb
Journal:  Biopolymers       Date:  1974-01       Impact factor: 2.505

7.  ADAMTS13 and von Willebrand factor and the risk of myocardial infarction in men.

Authors:  Chan K N K Chion; Carine J M Doggen; James T B Crawley; David A Lane; Frits R Rosendaal
Journal:  Blood       Date:  2006-10-19       Impact factor: 22.113

8.  Multimeric composition of factor VIII/von Willebrand factor following administration of DDAVP: implications for pathophysiology and therapy of von Willebrand's disease subtypes.

Authors:  Z M Ruggeri; P M Mannucci; R Lombardi; A B Federici; T S Zimmerman
Journal:  Blood       Date:  1982-06       Impact factor: 22.113

9.  Rapid high-resolution electrophoresis of multimeric von Willebrand Factor using a thermopiloted gel apparatus.

Authors:  Gary B Smejkal; John R Shainoff; Kandice M Kottke-Marchant
Journal:  Electrophoresis       Date:  2003-02       Impact factor: 3.535

Review 10.  An update on the von Willebrand factor collagen binding assay: 21 years of age and beyond adolescence but not yet a mature adult.

Authors:  Emmanuel J Favaloro
Journal:  Semin Thromb Hemost       Date:  2007-11       Impact factor: 4.180

View more
  5 in total

1.  Exponential size distribution of von Willebrand factor.

Authors:  Svenja Lippok; Tobias Obser; Jochen P Müller; Valentin K Stierle; Martin Benoit; Ulrich Budde; Reinhard Schneppenheim; Joachim O Rädler
Journal:  Biophys J       Date:  2013-09-03       Impact factor: 4.033

2.  Evaluation of a new semi-automated Hydragel 11 von Willebrand factor multimers assay kit for routine use.

Authors:  Marika Pikta; Timea Szanto; Margus Viigimaa; Sandra Lejniece; Dārta Balode; Kadri Saks; Valdas Banys
Journal:  J Med Biochem       Date:  2021-03-12       Impact factor: 3.402

3.  Preclinical evaluation of a semi-automated and rapid commercial electrophoresis assay for von Willebrand factor multimers.

Authors:  Marika Pikta; Galina Zemtsovskaja; Hector Bautista; Georges Nouadje; Timea Szanto; Margus Viigimaa; Valdas Banys
Journal:  J Clin Lab Anal       Date:  2018-02-17       Impact factor: 2.352

4.  Establishing reference intervals for von Willebrand factor multimers.

Authors:  Marika Pikta; Marc Vasse; Kristi J Smock; Karen A Moser; Dievoet Marie-Astrid van; Sandra Lejniece; Timea Szanto; Hector Bautista; George Nouadje; Valdas Banys
Journal:  J Med Biochem       Date:  2022-02-02       Impact factor: 3.402

5.  Integrated fluorescence correlation spectroscopy device for point-of-care clinical applications.

Authors:  Eben Olson; Richard Torres; Michael J Levene
Journal:  Biomed Opt Express       Date:  2013-06-11       Impact factor: 3.732

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.